Strategies & Technologies Driving Drug Discovery to Market
The Lead
Controlling Your Image
April 11, 2013 3:29 pm | by Mike May, Contributing Editor | Articles | Comments
Drug discovery and development depends increasingly on imaging, from traditional microscopy to high-content screening. Moreover, these techniques provide sophisticated capabilities. To make the most use of these tools, researchers need advanced software that provides automation, analysis, and ease-of-use.
Merck, Quintiles Sign Collaboration
May 17, 2013 11:42 am | News | Comments
In a novel approach to clinical development that is founded on a shared commitment to cost-...
Gilead Releases Positive Leukemia Data
May 17, 2013 11:18 am | News | Comments
Gilead Sciences Inc. announced results from a Phase 2 clinical trial evaluating idelalisib, an...
Halozyme Reports Pancreatic Cancer Study Data
May 16, 2013 4:39 pm | News | Comments
Halozyme Therapeutics Inc. has posted results from an early-stage trial that included its drug...
Impax Marketing Generic Zomig
May 17, 2013 10:46 am | News | CommentsImpax Laboratories Inc. is now selling a low-cost generic version of Zomig tablets and orally disintegrating Zomig tablets in two strengths. Zomig, or zolmitriptan, is available in tablet and nasal spray form and as tablets that will disintegrate and can be taken without liquid.
Zocor May Reduce Exercise Benefits
May 16, 2013 4:32 pm | News | CommentsStatins are often suggested to lower cholesterol and prevent heart disease in individuals with obesity, diabetes and metabolic syndrome, which is a combination of medical disorders including excess body fat and/or high levels of blood pressure, blood sugar and/or cholesterol. However...
FDA Approves Cancer Treatment
May 16, 2013 4:21 pm | News | CommentsThe U.S. Food and Drug Administration has approved Xofigo to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs. It is intended for men whose cancer has spread after receiving medical or surgical therapy to lower testosterone.
The Promise of Companion Diagnostics
May 16, 2013 4:04 pm | by Christopher P. Leamon, Vice President of Research; Endocyte Inc., West Lafayette, Ind. | Articles | CommentsAdvances in biotechnology, together with an improved understanding of the underlying biology of disease, have led to the pursuit of more effective targeted therapeutics and the subsequent development of companion diagnostics to identify appropriate patients.
Oncothyreon Releases Stimuvax Data
May 16, 2013 11:54 am | News | CommentsDrug developer Oncothyreon Inc. announced new clinical trial data about an experimental lung cancer treatment that failed to improve the overall survival rate. Oncothyreon said that it identified some patients who appeared to live longer after treatment with Stimuvax.
Prestige Turns 4Q Profit
May 16, 2013 7:04 am | by The Associated Press | News | CommentsPrestige Brands Holdings Inc. returned to a profit in its fiscal fourth quarter, benefiting from lower operating expenses and better sales of over-the-counter health care products. The company reported net income of $19.3 million for the three months ending March 31.
Study IDs Key Protein for Cell Death
May 15, 2013 12:16 pm | by Anne Trafton | News | CommentsA team of researchers have identified a key protein involved in an alternative death pathway known as programmed necrosis. Drugs that mimic the effects of this protein could push cancer cells that are resistant to apoptosis into necrosis instead.
FDA Grants Priority Review to Simeprevir
May 15, 2013 12:00 pm | News | CommentsThe U.S. Food and Drug Administration has granted Priority Review to Janssen's New Drug Application for simeprevir, an investigational NS3/4A protease inhibitor administered with pegylated interferon and ribavirin for the treatment of genotype 1 chronic hepatitis C.
Merck Debt Rating Takes Hit
May 14, 2013 6:11 pm | News | CommentsMoody's Investors Service has lowered the long-term debt ratings of drug maker Merck & Co. The rating agency put Merck on review for downgrade at the beginning of May following the company's plans to buy back about $7.5 billion worth of its shares over the next 12 months.
Hospira's Former CSO Returns
May 14, 2013 1:58 pm | News | CommentsHospira Inc. said that Dr. Sumant Ramachandra was coming back as senior vice president and chief scientific officer, just two months after he had left the company. Ramachandra left the company in March to be president of research and development at Synta Pharmaceuticals Corp.
Automating Biomolecular Research Processes with LEAP Instrument
May 14, 2013 9:51 am | by Fredrik Kamme, PhD, Vice President, Cell Engineering Unit; Marie L. Rossi, PhD, Manager, Technical Communications, Intrexon Corp., Blacksburg, Va. | Articles | CommentsDeveloping and maintaining cell lines for therapeutic bioproduction and biomedical research requires efficiency and accuracy. By automating the processes and techniques used in biomolecular research, scientists can achieve standardization, which can improve the speed, quality, and cost of drug discovery.
India Developing $1 Vaccine
May 14, 2013 9:21 am | by Ravi Nessman | News | CommentsThe Indian government announced the development of a new low-cost vaccine proven effective against a diarrhea-causing virus that is one of the leading causes of childhood deaths across the developing world. The Indian manufacturer of the new rotavirus vaccine pledged to sell it for $1 a dose.
Rebif Prices Push Merck Up 54%
May 14, 2013 5:46 am | by David McHugh | News | CommentsHigher prices for its multiple sclerosis drug Rebif helped German pharmaceutical and high-tech materials company Merck KGaA post a 54 percent rise in first-quarter profit. Merck also saw stronger sales of materials for liquid-crystal displays and raised its profit forecast, saying it would...
Optimer Names Sirota COO
May 13, 2013 4:59 pm | News | CommentsOptimer Pharmaceuticals said Monday that it has named Eric Sirota as its chief operating officer. The Jersey City, N.J., company said that Sirota has experience in building pharmaceutical brands and that his appointment fills a significant need at the company. Hank McKinnell, chairman and CEO of of Optimer, said the appointment allows him to focus on the strategic review process.
Impure Drugs Cost Ranbaxy $500M
May 13, 2013 2:28 pm | by Eric Tucker | News | CommentsA subsidiary of India's largest pharmaceutical company has agreed to pay $500 million in fines and civil penalties for selling adulterated drugs and lying about tests of the medications to federal regulators. Prosecutors said the guilty plea by Ranbaxy USA Inc. represents the largest financial penalty by a generic drug company for violations of the Federal Food, Drug and Cosmetic Act, which prohibits the sale of impure drugs.
